Skip to content

Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia

Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00331669
Enrollment
24
Registered
2006-05-31
Start date
2006-05-31
Completion date
2010-12-31
Last updated
2009-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystonia, Movement Disorder

Keywords

deep brain stimulation, pallidum, tardive dystonia, randomized, double blind, multicenter

Brief summary

The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.

Detailed description

Deep brain stimulation (DBS) has been established as a new reversible, neurosurgical therapeutic option for patients suffering from disabling neurological movement disorders such as essential tremor and Parkinson´s disease. Recently, deep brain stimulation has been successfully applied in patients with primary generalized and segmental dystonia. Additionally, a number of case reports suggest that pallidal deep brain stimulation may also improve tardive dystonia, which may for instance result from the intake of neuroleptics and which is notoriously difficult to treat medically. The present study will investigate the effects of pallidal DBS using a double blind, randomized design (sham- versus verum-stimulation within a 3-months interval post implantation of the electrodes). Initially 60 patients had been calculated in a power analysis to assess significant results based on an average improvement of dystonic symptoms of 30%. However, in a recent study (Damier et al., Archives of General Psychiatry, 2007), 10 out of 10 showed a successful outcome of approximately 50% decrease on the extrapyramidal symptoms rating scale score. The exact one- sided lower 95% confidence limit would be 0.794 for this result. If such an approach is chosen for sample size estimation with 18 verum and 18 placebo patients one would obtain a power of 82% against a placebo effect of 30% success rate. For a placebo effect of 25% one needs 16+16 patients and for the placebo effect of 20% one needs 12+12 patients. We thus decided to reduce the sample size to 36- 32- 24 patients. It is expected that the continuous primary outcome measure will preserve even higher power than the binary one used in the study mentioned above. The local ethical committee has approved this.

Interventions

PROCEDUREdeep brain stimulation

high frequency stimulation

Sponsors

Humboldt-Universität zu Berlin
CollaboratorOTHER
Ruhr University of Bochum
CollaboratorOTHER
Medical University of Cologne
CollaboratorOTHER
Heinrich-Heine University, Duesseldorf
CollaboratorOTHER
University Hospital Freiburg
CollaboratorOTHER
Medical University of Hannover
CollaboratorOTHER
Medical University Innsbruck
CollaboratorOTHER
University of Kiel
CollaboratorOTHER
Philipps University Marburg
CollaboratorOTHER
Ludwig-Maximilians - University of Munich
CollaboratorOTHER
University of Rostock
CollaboratorOTHER
University of Regensburg
CollaboratorOTHER
University Hospital Tuebingen
CollaboratorOTHER
Medical University of Vienna
CollaboratorOTHER
Medtronic
CollaboratorINDUSTRY
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Operational criteria for tardive dystonia for \> 18 months after cessation of neuroleptic exposure * 18-75 years * Relevant functional impairment in daily living activities * BFMDRS \> 8 or AIMS \> 16 * Informed written consent

Exclusion criteria

* PANNS \>60 (Schizophrenia) * Hamilton-Score \> 18 (Depression) * MATTIS-Score \<120 (Dementia) * Preceding stereotactic neurosurgery * Pronounced brain atrophy * Increased bleeding risk * Decreased immune status * Botulinum Toxin treatment within the last 3 months

Design outcomes

Primary

MeasureTime frame
Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale via blinded video assessment 3 months after starting DBS in comparison to sham-stimulated patients3 months

Secondary

MeasureTime frame
AIMS3 months
Non-motor subscores of BMFDRS3 months
Visual analogue scales for both patients and treating physicians3 months
Quality of life (SF-36)3 months
Psychiatric assessment (HADS-D and PANSS)3 months

Countries

Germany

Contacts

Primary ContactAndreas R Kupsch, MD, PhD
andreas.kupsch@charite.dexx49-30-450-50
Backup ContactAndrea Kuehn, MD
andrea.kuehn@charite.dexx49-30-450-50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026